Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283039> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W4379283039 endingPage "3038" @default.
- W4379283039 startingPage "3038" @default.
- W4379283039 abstract "3038 Background: A double-blind clinical study was conducted on 304 clinically verified blood serum samples, including 141 non-small cell lung cancer (NSCLC), 133 healthy volunteers and 30 patients with chronic obstructive pulmonary disease (COPD). The objectives of the study were: The assessment of various cancer markers and their possible combinations for detection of early (I-II) stages of non-small cell lung cancer (NSCLC) and evaluation of the best cancer markers panel as a pre-screening tool for NSCLC before Low-Dose CT scan. Methods: Quantitative measurement of various tumor markers for serum samples was carried out using electrochemiluminescent immunoassays Elecsys CA-125, ELECSYS CA 19-9, ELECSYS CYFRA 21-1 and ELECSYS SCC (COBAS, Roche Diagnostics GmbH, Germany, EU), enzyme immunoassay CA15-3-ELISA-BEST, CEA-ELISA-BEST, NSE-ELISA-BEST (JSC VECTOR-BEST, RF) and immunochemiluminescent analysis CLIA-CA-62 (LLC JVS Diagnostics, RF). The results were compared to the literature data for other biomarkers and their panels. Results: Unlike other tumor markers, which are expressed proportionally to tumor size, the marker for epithelial carcinomas CA-62 is expressed from Stage I and demonstrated the highest diagnostic results in detecting early stages (I-II) of NSCLC. The biomarkers CYFRA 21-1 and SCC do not have sufficient sensitivity and specificity to diagnose asymptomatic lung cancer. However, the addition of cytokeratin 19 CYFRA 21-1 to glycoproteins CA-62 and CEA increases the specificity by eliminating false positive results, which significantly improves the diagnostic value of the cancer marker signature (CA-62, CEA and CYFRA 21-1): 100% Specificity, 93% Sensitivity, 100% PPV, 94% NPV and 94% test accuracy. Conclusions: The results of the study demonstrated that using the biomarkers signature (CA-62, CEA and CYFRA 21-1) allows increasing the specificity of CT scan for patients with suspicious abnormalities on the tomogram, improving the interpretation of visualized localized lesion, and improving the accuracy of differential diagnosis at detecting early stages of LC up to 94%. In the prospective, adding cancer markers panel signature (CA-62, CEA and CYFRA 21-1) to the current lung cancer risk assessment system as a pre-screening tool for LDCT may improve the quality of early-stage Lung cancer detection by significant increasing the sensitivity and by reducing the proportion of false positive results. [Table: see text]" @default.
- W4379283039 created "2023-06-05" @default.
- W4379283039 creator A5006377861 @default.
- W4379283039 creator A5027941893 @default.
- W4379283039 creator A5029085058 @default.
- W4379283039 creator A5029460219 @default.
- W4379283039 creator A5043771424 @default.
- W4379283039 creator A5072014525 @default.
- W4379283039 creator A5078468751 @default.
- W4379283039 creator A5089922247 @default.
- W4379283039 date "2023-06-01" @default.
- W4379283039 modified "2023-09-25" @default.
- W4379283039 title "A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection." @default.
- W4379283039 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.3038" @default.
- W4379283039 hasPublicationYear "2023" @default.
- W4379283039 type Work @default.
- W4379283039 citedByCount "0" @default.
- W4379283039 crossrefType "journal-article" @default.
- W4379283039 hasAuthorship W4379283039A5006377861 @default.
- W4379283039 hasAuthorship W4379283039A5027941893 @default.
- W4379283039 hasAuthorship W4379283039A5029085058 @default.
- W4379283039 hasAuthorship W4379283039A5029460219 @default.
- W4379283039 hasAuthorship W4379283039A5043771424 @default.
- W4379283039 hasAuthorship W4379283039A5072014525 @default.
- W4379283039 hasAuthorship W4379283039A5078468751 @default.
- W4379283039 hasAuthorship W4379283039A5089922247 @default.
- W4379283039 hasConcept C111683008 @default.
- W4379283039 hasConcept C118646709 @default.
- W4379283039 hasConcept C121608353 @default.
- W4379283039 hasConcept C126322002 @default.
- W4379283039 hasConcept C142724271 @default.
- W4379283039 hasConcept C143998085 @default.
- W4379283039 hasConcept C146357865 @default.
- W4379283039 hasConcept C151730666 @default.
- W4379283039 hasConcept C159654299 @default.
- W4379283039 hasConcept C185592680 @default.
- W4379283039 hasConcept C203014093 @default.
- W4379283039 hasConcept C204232928 @default.
- W4379283039 hasConcept C2776256026 @default.
- W4379283039 hasConcept C2777910003 @default.
- W4379283039 hasConcept C2779012181 @default.
- W4379283039 hasConcept C2780420688 @default.
- W4379283039 hasConcept C2781197716 @default.
- W4379283039 hasConcept C2781447364 @default.
- W4379283039 hasConcept C530470458 @default.
- W4379283039 hasConcept C55493867 @default.
- W4379283039 hasConcept C71924100 @default.
- W4379283039 hasConcept C86803240 @default.
- W4379283039 hasConceptScore W4379283039C111683008 @default.
- W4379283039 hasConceptScore W4379283039C118646709 @default.
- W4379283039 hasConceptScore W4379283039C121608353 @default.
- W4379283039 hasConceptScore W4379283039C126322002 @default.
- W4379283039 hasConceptScore W4379283039C142724271 @default.
- W4379283039 hasConceptScore W4379283039C143998085 @default.
- W4379283039 hasConceptScore W4379283039C146357865 @default.
- W4379283039 hasConceptScore W4379283039C151730666 @default.
- W4379283039 hasConceptScore W4379283039C159654299 @default.
- W4379283039 hasConceptScore W4379283039C185592680 @default.
- W4379283039 hasConceptScore W4379283039C203014093 @default.
- W4379283039 hasConceptScore W4379283039C204232928 @default.
- W4379283039 hasConceptScore W4379283039C2776256026 @default.
- W4379283039 hasConceptScore W4379283039C2777910003 @default.
- W4379283039 hasConceptScore W4379283039C2779012181 @default.
- W4379283039 hasConceptScore W4379283039C2780420688 @default.
- W4379283039 hasConceptScore W4379283039C2781197716 @default.
- W4379283039 hasConceptScore W4379283039C2781447364 @default.
- W4379283039 hasConceptScore W4379283039C530470458 @default.
- W4379283039 hasConceptScore W4379283039C55493867 @default.
- W4379283039 hasConceptScore W4379283039C71924100 @default.
- W4379283039 hasConceptScore W4379283039C86803240 @default.
- W4379283039 hasIssue "16_suppl" @default.
- W4379283039 hasLocation W43792830391 @default.
- W4379283039 hasOpenAccess W4379283039 @default.
- W4379283039 hasPrimaryLocation W43792830391 @default.
- W4379283039 hasRelatedWork W150275630 @default.
- W4379283039 hasRelatedWork W1940857293 @default.
- W4379283039 hasRelatedWork W2029559096 @default.
- W4379283039 hasRelatedWork W2037309347 @default.
- W4379283039 hasRelatedWork W2045073158 @default.
- W4379283039 hasRelatedWork W2063851783 @default.
- W4379283039 hasRelatedWork W2106006593 @default.
- W4379283039 hasRelatedWork W4235884581 @default.
- W4379283039 hasRelatedWork W4365444059 @default.
- W4379283039 hasRelatedWork W4379283039 @default.
- W4379283039 hasVolume "41" @default.
- W4379283039 isParatext "false" @default.
- W4379283039 isRetracted "false" @default.
- W4379283039 workType "article" @default.